BSV introduces Adverse Event Reporting Application: Pivotal stride in strengthening Patient’s safety

New Delhi: Bharat Serums and Vaccines Limited (BSV), one of India’s leading biopharmaceutical companies, announced the launch of a new communication tool- ‘BSV AER’. This mobile-based application offers a powerful platform which is designed to streamline the reporting of potential adverse events that may occur following the use of BSV products.

BSV AER is directly connected to BSV’s pharmacovigilance system, which allows Healthcare Professionals (HCPs), consumers and the company personnel to report these electronically from their smartphones or tablets from any location within India and is free of cost to it users.

The mobile application is simple to use and very convenient for uploading information about potential adverse events, which can lead to timely reporting without the risk of loss of any important information about the event. This in turn can help the company’s medical and scientific personnel to evaluate the reported event and provide prompt response to HCPs and to the consumers for the effective management of applicable adverse events.

Sanjiv Navangul, MD & CEO, BSV said, “As the pharmaceutical industry continues to evolve, the need for robust adverse event reporting tools is vital. We are confident that the BSV AER application will represent an important milestone in advancing pharmacovigilance practices in India.  The safety and well-being of patients with health conditions managed with medications, both developed and marketed by BSV,  is crucial. There is a need to communicate with HCPs regarding both the beneficial as well as adverse events that may be experienced by patients under their care. The BSV AER application not only allows for dissemination of information, it also helps our commercial teams to collect safety information from HCPs in an efficient manner, thereby creating a robust pharmacovigilance practice that strengthens patient safety.”

Dr Swashraya Shah, Chief Medical Officer, BSV said, “It is only through careful analysis of adverse events reported by HCPs and consumers, the pharmaceutical industry and authorities can assess the incidence of adverse events, and where these are serious or unexpected.  As part of our pharmacovigilance practice, we at BSV thoroughly assess every adverse event to enhance our knowledge of our medicines, and share this with HCPs, thereby enabling an effective management of patients treated by BSV’s medicinal products.  Patient safety is the core of everything we do, and we are proud to launch BSV AER application which reaffirms our commitment to the safety of patients who receive the medicines that have been developed and marketed in India by the company.”